Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (341-350 of 419) with videos related to

Pageof 42
Sort By:
Contemporary Clinical Trials|September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapseBhavna Oza, Eleni Frangou, Ben Smith, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
The Lancet. Oncology|February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trialJanet E Brown, Kara-Louise Royle, Walter Gregory, et al.
Genome Research|November 24, 2006
Accurate and reliable high-throughput detection of copy number variation in the human genomeHeike Fiegler, Richard Redon, Dan Andrews, et al.
Journal for Immunotherapy of Cancer|January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 studyJason Chesney, Karl D Lewis, Harriet Kluger, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2017
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group studyEmeline Colomba, Gwénaël Le Teuff, Tim Eisen, et al.
The New England Journal of Medicine|June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutationPaul B Chapman, Axel Hauschild, Caroline Robert, et al.
The New England Journal of Medicine|February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaRobert J Motzer, Konstantin Penkov, John Haanen, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.
Pageof 42

Showing results (341-350 of 419) with videos related to

Sort By:
Pageof 42
Contemporary Clinical Trials|September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapseBhavna Oza, Eleni Frangou, Ben Smith, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
The Lancet. Oncology|February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trialJanet E Brown, Kara-Louise Royle, Walter Gregory, et al.
Genome Research|November 24, 2006
Accurate and reliable high-throughput detection of copy number variation in the human genomeHeike Fiegler, Richard Redon, Dan Andrews, et al.
Journal for Immunotherapy of Cancer|January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 studyJason Chesney, Karl D Lewis, Harriet Kluger, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2017
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group studyEmeline Colomba, Gwénaël Le Teuff, Tim Eisen, et al.
The New England Journal of Medicine|June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutationPaul B Chapman, Axel Hauschild, Caroline Robert, et al.
The New England Journal of Medicine|February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaRobert J Motzer, Konstantin Penkov, John Haanen, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.
Pageof 42